Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03442101 · ClinicalTrials.gov registry record

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

A clinical trial of Psychosis, sponsored by University of Alabama at Birmingham.

Active
Registry status
156
Enrollment target
1
Study location

NCT03442101 is a study of Psychosis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 156 participants, below the 174-participant average among 35 other Psychosis trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03442101, a study of Psychosis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.

ACTIVE NOT RECRUITING
Registry status
156 participants
Enrollment target
1
Study location

Study Summary

Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.

Conditions Studied

Interventions

  • DRUG Patients with psychosis will be treated with known antipsychotic medication

Study Locations (1)

Alabama

  • Sparks Center - Birmingham

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2018-04-01
Est. Completion 2026-12-31

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03442101

The ClinicalTrials.gov registry entry for NCT03442101 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 35 other Psychosis trials with a reported enrollment target (10% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psychosis appearing as the primary indexed condition, and to 1 intervention - of which Patients with psychosis will be treated with known antipsychotic medication is the first listed.

NCT03442101 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT03442101 about?

NCT03442101 is a clinical study titled "Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study". Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modali...

What is the current status of trial NCT03442101?

This trial is currently active not recruiting. The enrollment target is 156 participants. The study started on 2018-04-01. Estimated completion is 2026-12-31.

What conditions does trial NCT03442101 study?

This clinical trial studies the following conditions: Psychosis.

What interventions are being tested in trial NCT03442101?

The interventions under investigation include: Patients with psychosis will be treated with known antipsychotic medication (DRUG).

Who is sponsoring clinical trial NCT03442101?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03442101 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psychosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.